Positive News SentimentPositive NewsNASDAQ:MDNA Medicenna Therapeutics (MDNA) Stock Forecast, Price & News $0.59 -0.02 (-3.28%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$0.58▼$0.6050-Day Range$0.52▼$0.8252-Week Range$0.40▼$1.88Volume7,262 shsAverage Volume100,681 shsMarket Capitalization$41.09 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Medicenna Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside959.1% Upside$6.25 Price TargetShort InterestHealthy0.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.20) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector653rd out of 1,006 stocksPharmaceutical Preparations Industry327th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingMedicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.25, Medicenna Therapeutics has a forecasted upside of 959.1% from its current price of $0.59.Amount of Analyst CoverageMedicenna Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.69% of the float of Medicenna Therapeutics has been sold short.Short Interest Ratio / Days to CoverMedicenna Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medicenna Therapeutics has recently increased by 20.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedicenna Therapeutics does not currently pay a dividend.Dividend GrowthMedicenna Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDNA. Previous Next 2.7 News and Social Media Coverage News SentimentMedicenna Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.Search InterestOnly 7 people have searched for MDNA on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Medicenna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders33.10% of the stock of Medicenna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.68% of the stock of Medicenna Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.20) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicenna Therapeutics is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicenna Therapeutics is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedicenna Therapeutics has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Medicenna Therapeutics (NASDAQ:MDNA) StockMedicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.Read More Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MDNA Stock News HeadlinesMay 18, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp down on Wednesday (MDNA)May 17, 2023 | americanbankingnews.comMedicenna Therapeutics Corp. (NASDAQ:MDNA) Short Interest Up 5.8% in AprilMay 31, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 16, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp down on Monday (MDNA)May 6, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp flat on Friday (MDNA)April 29, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp down on Friday (MDNA)April 27, 2023 | finance.yahoo.comMedicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price RequirementApril 22, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp up on Friday (MDNA)May 31, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...April 21, 2023 | americanbankingnews.comShort Interest in Medicenna Therapeutics Corp. (NASDAQ:MDNA) Rises By 9.9%April 19, 2023 | msn.comMDNA: Update on ABILITY Trial…April 19, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn SituationApril 18, 2023 | finance.yahoo.comMedicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 17, 2023 | finance.yahoo.comMedicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual MeetingMarch 30, 2023 | finance.yahoo.comMedicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY StudyMarch 15, 2023 | finance.yahoo.comMedicenna Announces Upcoming Presentation at the AACR Annual MeetingFebruary 7, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational HighlightsFebruary 7, 2023 | finance.yahoo.comMedicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational HighlightsJanuary 31, 2023 | finance.yahoo.comMedicenna to Present at the 2023 Guggenheim Oncology ConferenceDecember 10, 2022 | theglobeandmail.comMedicenna Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (MDNA)November 16, 2022 | finance.yahoo.comMDNA: Enrollment Continues in the Fifth Dosing Cohort of the ABILITY Trial…November 4, 2022 | seekingalpha.comMedicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q2 2023 Earnings Call TranscriptNovember 4, 2022 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational HighlightsNovember 4, 2022 | finance.yahoo.comMedicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational HighlightsOctober 25, 2022 | finance.yahoo.comMedicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022September 30, 2022 | finance.yahoo.comMedicenna Extends Period to Exercise Certain WarrantsSeptember 22, 2022 | finance.yahoo.comMedicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MDNA Company Calendar Last Earnings11/12/2021Today5/31/2023Next Earnings (Estimated)6/28/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDNA CUSIPN/A CIK1807983 Webwww.medicenna.com Phone(416) 648-5555Fax416-572-7501Employees13Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.25 High Stock Price Forecast$10.00 Low Stock Price Forecast$2.50 Forecasted Upside/Downside+316.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-60.96% Return on Assets-54.14% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book2.00Miscellaneous Outstanding Shares69,640,000Free Float46,587,000Market Cap$41.78 million OptionableNot Optionable Beta1.23 Key ExecutivesFahar MerchantChairman, President & Chief Executive OfficerElizabeth WilliamsChief Financial Officer & SecretaryMartin BexonChief Medical OfficerRosemina MerchantDirector & Chief Development OfficerKey CompetitorsUnity BiotechnologyNASDAQ:UBXProMIS NeurosciencesNASDAQ:PMNNuCanaNASDAQ:NCNAGenprexNASDAQ:GNPXTherapeuticsMDNASDAQ:TXMDView All CompetitorsInstitutional OwnershipHudson Bay Capital Management LPSold 110,300 shares on 5/16/2023Ownership: 1.183%Renaissance Technologies LLCSold 26,242 shares on 5/12/2023Ownership: 0.216%View All Institutional Transactions MDNA Stock - Frequently Asked Questions Should I buy or sell Medicenna Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDNA shares. View MDNA analyst ratings or view top-rated stocks. What is Medicenna Therapeutics' stock price forecast for 2023? 3 Wall Street analysts have issued 1 year target prices for Medicenna Therapeutics' stock. Their MDNA share price forecasts range from $2.50 to $10.00. On average, they anticipate the company's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 941.7% from the stock's current price. View analysts price targets for MDNA or view top-rated stocks among Wall Street analysts. How have MDNA shares performed in 2023? Medicenna Therapeutics' stock was trading at $0.4580 at the beginning of 2023. Since then, MDNA stock has increased by 31.0% and is now trading at $0.60. View the best growth stocks for 2023 here. When is Medicenna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 28th 2023. View our MDNA earnings forecast. How were Medicenna Therapeutics' earnings last quarter? Medicenna Therapeutics Corp. (NASDAQ:MDNA) issued its earnings results on Friday, November, 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.03. During the same period in the previous year, the firm earned ($0.06) EPS. What is Medicenna Therapeutics' stock symbol? Medicenna Therapeutics trades on the NASDAQ under the ticker symbol "MDNA." Who are Medicenna Therapeutics' major shareholders? Medicenna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hudson Bay Capital Management LP (1.18%) and Renaissance Technologies LLC (0.22%). How do I buy shares of Medicenna Therapeutics? Shares of MDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Medicenna Therapeutics' stock price today? One share of MDNA stock can currently be purchased for approximately $0.60. How much money does Medicenna Therapeutics make? Medicenna Therapeutics (NASDAQ:MDNA) has a market capitalization of $41.78 million. The company earns $-18,010,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis. How can I contact Medicenna Therapeutics? Medicenna Therapeutics' mailing address is 200-1920 Yonge Street, Toronto A6, M4S 3E2. The official website for the company is www.medicenna.com. The company can be reached via phone at (416) 648-5555, via email at ir@medicenna.com, or via fax at 416-572-7501. This page (NASDAQ:MDNA) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.